




VISION 2026

STAAR Surgical Investor Day

September 14, 2023

NASDAQ: STAA



Agenda

Time EDT	Topic	Speaker
8:30 a.m.	Welcome / Safe Harbor	Brian Moore, Investor Relations
	Vision 2026: Achieving STAAR's Global Growth Opportunity	Tom Frinzi, Chair of the Board and CEO
	Extending EVO ICL's Leadership Position	Magda Michna, PhD Chief Clinical, Regulatory and Medical Affairs Officer
	China: Durable Growth in the Largest Refractive Market Globally	Zheng Wang, MD Chief Medical Officer, Refractive Surgery, Aier Eye Hospital Group (China)
9:20 a.m.	Q&A Session 1	
9:30 a.m.	BREAK	
9:45 a.m.	U.S. Refractive Market: From LASIK to Lens-Based	Stephen Slade, MD (United States)
	Establishing EVO ICL as The First Choice for Doctors and Patients	Warren Foust, Chief Operating Officer
	Surgeon Panel: The Global EVO ICL Experience	Scott Barnes, MD, Chief Medical Officer (Moderator) Frank Kerkoff, MD (Netherlands) Stephen Slade, MD (United States) Blake Williamson, MD (United States) Zheng Wang, MD (China) Roger Zaldivar, MD (Argentina)
10:50 a.m.	BREAK	
11:05 a.m.	Long Term Plan and Value Creation	Patrick Williams, Chief Financial Officer
	Closing Remarks	Tom Frinzi, Chair of the Board and CEO
11:20 a.m.	Q&A Session 2	
11:50 a.m.	Investor Day Concludes	



SCAN FOR MORE INFORMATION

Forward Looking Statements and Non-GAAP Financial Measures

All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2023 through 2026 or prospects for achieving such plans, expectations for sales, revenue, margin, expenses or earnings, and any statements of assumptions underlying any of the foregoing, including those relating to financial performance in the third quarter and fiscal years 2023 through 2026.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include risks and uncertainties related to the COVID-19 pandemic and related public health measures, as well as the factors set forth in the Company's Annual Report on Form 10-K for the year ended December 30, 2022 under the caption "Risk Factors," which is on file with the Securities and Exchange Commission and available in the "Investor Information" section of the company's website under the heading "SEC Filings."

We disclaim any intention or obligation to update or revise any financial projections or forward-looking statement due to new information or events. These statements are based on expectations and assumptions as of the date of this presentation and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: global economic conditions; the impact of the COVID-19 pandemic on markets; the discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before approval, or to take enforcement action; international trade disputes; and the willingness of surgeons and patients to adopt a new or improved product and procedure.

This presentation includes supplemental Non-GAAP financial information, which STAAR believes investors will find helpful in understanding its operating performance. Non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Please refer to the Company's Form 8-K filed on August 2, 2023, which is on file with the Securities and Exchange Commission, concerning the use of Non-GAAP Financial Measures and the applicable reconciliation tables.




VISION 2026

Achieving STAAR's Global Growth Opportunity

TOM FRINZI

Chair of the Board and CEO
STAAR Surgical Company

Vision 2026 / Exciting Global Growth



**The first Choice for
Doctors and Patients
Seeking Visual Freedom**

Vision 2026 / Growth Foundation



- 1 Invest in Largest Market Opportunities
- 2 Drive EVO ICL Awareness
- 3 Enhance Surgeon Support and Education
- 4 Introduce New Products
- 5 Create a High Performance Organization

Vision 2026 / Double-Digit Sales CAGR



TARGET SALES
MODEL

 STAARSURGICAL

Approximately

15%

TO

Approximately

20%

ANNUAL GROWTH RANGE Y/Y

3-Year Sales CAGR (2024-2026)




Approximately

\$500 TO \$550 MILLION

Fiscal 2026 Sales

Select Growth Markets (3-Year CAGR, 2020-2022)

Our History of 15%+ Global ICL Sales Growth



Our Large Market Opportunity


Global Myopia Epidemic




Today: **Every third person** in the world



2050: **Every other person** in the world *



Normal



Myopia

Key Factors with Myopia




Genetic Predisposition



Environmental Factors



Billions of People



*BHVI, adapted from Holden et al. 2016 Ophthalmology. 36% of studies defined high myopia as -6.0D or more..

Non-Surgical
Myopia Correction Options




Myopia Management

May reduce, but does not eliminate Myopia



Glasses

Limits certain activities and lifestyles



Contact Lenses

May cause dry eyes




Surgical Myopia Correction Options

Refractive Procedures

- ✓ Laser Vision Correction (LASIK, PRK, SMILE)
- ✓ Lens-Based (EVO ICL)



Laser Vision Correction in Decline





Achieving STAAR's Global Growth Opportunity
Investing in the Largest Markets

China

34%
of 4.5M Estimated
Procedures in
2023


U.S.

17%
of 4.5M Estimated
Procedures in
2023



Top 15 Markets

83%
of 4.5 Estimated Procedures in 2023

Top 15 Refractive Procedure Markets



Achieving STAAR's Global Growth Opportunity
Investing in Fastest Growing Markets



 **+462,441** Expected Procedure Growth

 **Global Procedures expected to grow from 4.5M to ~5.0M*** 

Milestone Sales Achievements

TOTAL ICLs
SOLD...

1 M

1999 - 2Q19

~ 20 YEARS

2 M

2Q22

~ 3 YEARS

3 M

1Q24E

< 2 YEARS

6 M

4Q26E

VISION 2026

STAAR expects to sell more ICLs in the next three years (2024-2026) than the first 25 years of ICL sales combined.

Robust Product Pipeline



Creating a High Performance Organization



VISION

- + Exciting Global Growth
- + The first Choice for Doctors and Patients Seeking Visual Freedom



Corporate Values



Voice of Customer



Voice of Employees



Facts and Data Driven Organization



VITAL FEW PROJECTS AND INVESTMENTS



THE ORGANIZATION STRUCTURE & TEAM TO EXECUTE

The STAAR Team / Up Next...



Magda Michna, PhD

- › STAAR's Proprietary EVO ICL Technology
- › Robust Product Pipeline
- › Increasing Surgeon Support and Education



Warren Foust

- › Continuing EVO ICL's Global Growth – APAC, EMEA, Americas
- › Driving EVO ICL Awareness
- › Commercial Initiatives to Accelerate Growth
- › Operational Excellence and Scale to Sell Millions of EVOs Annually



Patrick Williams

- › STAAR's Financial Strength
- › Target Sales and Operating Model
- › Financial Discipline



VISION 2026

Extending EVO ICL's Leadership Position

MAGDA MICHNA, PHD

Chief Clinical, Regulatory and Medical Affairs Officer
STAAR Surgical Company

01

The Collamer®
Difference


02

Robust
Product
Pipeline

03

Surgeon Support
and Education

EVO ICL – The Collamer® Difference



Collamer®

Collamer is a proprietary lens material created and used exclusively by STAAR®.

The Collamer material is bonded with UV absorbing chromophore into a copolymer that offers UV protection.



Collagen

Collagen is the main structural protein in the extracellular matrix found in the body's various connective tissues.



It is the most abundant protein in mammals, making up from 25% to 35% of the whole-body protein content.

Collagen forms the structural component of tendons, ligaments, bones and joints.



Safety and Effectiveness

- + Proven track record of sound scientific evidence supporting performance and safety of EVO:
- + Two pivotal US clinical trials determined the safety and performance of the ICL in >500 patients.



200+

ICL Clinical Papers

32%

200/629 eyes in U.S. EVO FDA study had -3D to -6D SE. 2, 3

1%

Global MDR rate past six quarters⁴

2-3%

U.S. MDR rate on FDA MAUDE database (past six quarters) is consistent with early EVO experience in other countries⁴

The EVO ICL Advantage: A Disruptive Technology

Sharp, clear
vision

Excellent
vision at night

Does not cause
dry eye
syndrome

Quick
procedure and
recovery

Bio-
Compatible

No removal of
corneal tissue

Removable by
a surgeon

Protection
from UV rays

Additive

Quiet in the
Eye

Only One Phakic Intraocular Lens (IOL) Is Collamer

EVO ICL – Posterior Chamber / Collamer

- ✓ Posterior chamber – the narrow space behind the iris and in front of the natural crystalline lens
- ✓ **Collamer**, A unique biocompatible material
- ✓ Approaching 3M+ lenses sold
- ✓ ~25 Year history of safety and effectiveness
- ✓ 99.4% of EVO patients surveyed would choose EVO again*

* Packer, The Implantable Collamer Lens with a central port: review of the literature, Clinical Ophthalmology, 2018.

vs.

Other Phakic IOLs

- ✓ **Cachet Lens** – Anterior Chamber / **Acrylic**
Due to concerns about endothelial cells loss in a group of 1323 eyes implanted, the manufacturer voluntarily discontinued the production of this intraocular lens in 2014.
- ✓ **Verisyse Artisan Lens** – Anterior Chamber / **Acrylic**
- ✓ **IPCL V2.0 Lens** – Posterior Chamber / **Acrylic**
- ✓ **EYECRYL™ Lens** – Posterior Chamber / **Acrylic**
- ✓ **Eyebright Lens** – Posterior Chamber / **Acrylic**

+ Approx. 16 Other Phakic IOLs

STAAR Listens

The Voice of Our Global Customers

Current State

93%

Global Surgeon Willingness to Recommend

(N=907, April 13, 2023)

Two Survey Questions

What do you recommend STAAR do to increase your adoption of our ICLs?

If STAAR could improve one or two important things, what would you recommend?"

o o o



Our Opportunity

Faster Delivery/Supply

Marketing/Consumer Awareness

Order Process/Product Availability

TRAINING ON LENS SIZE SELECTION

More Lens Sizes

Pre-Op Measurement

Robust Product Pipeline



Product Pipeline: Presbyopia

EVO VIVA

EVO VIVA™

is an extended depth of focus (EDoF) lens

➤ Surgeon training and education on lens and patient selection are critical variables for success

- Expands EVO ICL family of lenses to early presbyopes ages 45-55
- Removable and saves crystalline lens
- Expanded commercialization post ESCRS

 STAAR SURGICAL



An innovative Implantable Collamer® Lens for the correction/reduction of myopia with presbyopia

Product Pipeline: Lens Delivery Devices
ACCUJECT Injector System

Voice of customer

Partnered w/ Medice – a global leader in injector systems

Custom designed injector system for EVO/EVO+ ICLs

Launch strategy begins in US then global expansion

PHASE 1
User Loaded Injector

2024



PHASE 2
Pre-loaded Injector

2026




Product Pipeline: ICL Planning and Ordering System Stella



Optimized User Interface
and Workflow



- Patient Management
- Intuitive Calculator
- Order Management
- Inventory / Lens Reservations



- + Upgrade replacement for OCOS online calculator and ordering system

- + Significant time savings for customers estimated at up to 15 minutes per patient


- + Development roadmap includes integration with widely used biometer and diagnostic devices, e.g. Pentacam



Launch 2024


Product Pipeline: A New Lens for the World's Largest Refractive Market

EVO+ ICL in China




Product Pipeline

Next Generation EVO Lenses



Surgeon Support and Education

Benchmark and leverage international expertise to support surgeon journey in the US





CHINA:

Durable Growth in the Largest Refractive Market Globally

ZHENG WANG, MD

Aier Eye Hospital Group
Shanghai, China

Refractive Surgery in China – the Big Data

Wang Zheng, MD

第二届爱尔 EVO ICL 国际论坛

The 2nd Aier EVO ICL International Summit



Myopia: The Present Situation

- Myopia prevalence in Asia is higher than Europe and US. China has reached 48.5%, the highest prevalence of myopia in Asia

Race (Tay's)	All Ages
Chinese	48.5%
Eurasian	34.7%
Indians	30.4%
Malays	24.5%

Source: Archives of Ophthalmology, Aug 2008; Singapore Medical Journal, Dec1993



Refractive Surgery Penetration Rate

- Myopia prevalence in Asia is higher than Europe and US. While LVC per 1k population in China is only 0.7 while Western Europe reached 1.3 and USA 2.6.

Market Scope: 2021 Refractive Surgery Market Report				
Laser Vision Correction Procedures by Country and Annual Rate				
Region	Country	Population (M)	% of Global Population	LVC per 1k Population
	United States	335.0	4.30%	2.6
	Germany	80.0	1.0%	1.3
	France	68.1	0.9%	1.1
	United Kingdom	66.1	0.9%	1.3
Western Europe	Italy	62.5	0.8%	1.2
	Spain	50.3	0.6%	1.6
	Other W. Europe	89.3	1.1%	1.3
	Total Western Europe	416.2	5.4%	1.3
	Japan	125.1	1.6%	0.4
	Korea, South	52.0	0.7%	3.8
	Canada	38.0	0.5%	2.3
Other Wealthy Nations	Saudi Arabia	34.7	0.4%	1.2
	Austria	25.8	0.3%	1.1
	Other Wealthy	89.3	1.2%	1.4
	Total OWN	263.5	3.4%	2.0
	Wealthy National Total	1139.8	14.7%	1.6
	China	1397.9	18.0%	0.7
	India	1340.5	17.3%	0.2

Market Scope: 2021 Refractive Surgery Market Report					
Laser Vision Correction Procedures by Country and Annual Rate					
Region	Country	Population (M)	% of Global Population	LVC per 1k Population	
Latin America	Brazil	213.1	2.7%	0.7	
	Mexico	130.0	1.7%	0.6	
	Columbia	49.5	0.6%	0.5	
	Argentina	45.9	0.6%	0.4	
	Peru	32.2	0.4%	0.2	
	Venezuela	29.1	0.4%	0.0	
	Other LA	146.6	1.90%	0.2	
	Total LA	646.3	8.30%	0.5	
	Rest of World	Indonesia	269.1	3.50%	0.1
		Pakistan	238.3	3.10%	0.0
Poland		38.2	0.50%	0.4	
Russia		141.5	1.80%	0.5	
Thailand		69.1	0.90%	0.8	
Philippines		110.8	1.40%	0.2	
Egypt		106.5	1.40%	0.8	
Vietnam		99.5	1.30%	0.3	
Turkey		82.5	1.10%	0.9	
Other ROW		2086.3	26.90%	0.0	
Total ROW		3241.7	41.70%	0.1	

Source: Market Scope: 2021 Refractive Surgery Market Report

Big Data Report in Aier Group



Research Period

2018-2021



Research Population

Refractive surgery patients in Aier China and
Clínica Baviera



Research Data

Valid Data
1,830,981 eyes/
931,071 patients




Research Region

Mainland China
Spain
Italy
Germany
Austria




Surgical Volume




Seasonality Trends

Aier China




Aier Europe



Patient Age


	Average Age	> 40 y/o
Aier China	25.5	3.6%
Aier Europe	33.3	21.7%




Gender

	Male	Female
Aier China	57.5%	42.5%
Aier Europe	49.7%	50.3%

Aier China



Aier Europe



Degree of Refractive Error

	Low Myopia (below -3D)	Moderate Myopia (-3 to -6D)	High Myopia (-6 to -10D)	Extreme Myopia (above -10D)
Aier China	13.3%	53.7%	29.8%	3.1%
Aier Europe (Clinica Baviera)	40.1%	41.0%	11.6%	1.3%



Growth ICL Volume in Aier Group

2014	Approval of V4c (EVO)
2015	36%
2016	68%
2017	85%
2018	82%
2019	45%
2020	31%
2021	22%
2022	17%

CAGR in the past 4 years:

LVC: **18.6%**

ICL: **28.0%**



Surgery Type




Year	Low Myopia (below -3D)		Moderate Myopia (-3 to -6D)		High Myopia (-6 to -10D)		Extreme Myopia (above -10D)	
	NO.1	NO.2	NO.1	NO.2	NO.1	NO.2	NO.1	NO.2
2021	SMILE 46.6%	LASIK 46.2%	SMILE 46.8%	LASIK 45.4%	LASIK 52.8%	ICL 23.3%	ICL 93.6%	LASIK 6.0%
2018-2020	LASIK 56.2%	SMILE 35.1%	LASIK 51.9%	SMILE 38.8%	LASIK 55.9%	SMILE 21.0%	ICL 49.7%	LASIK 31.7%



ICL Trends

Year	Low to moderate myopic ICL surgery
2021	2.9%
2018	1.5%

ICL CGAR (Y2018-Y2021)



UCVA on Day 1

81.79% ↑

(80.88% in 2018-2020)


UCDA
(post-op) \geq **BCVA**
(pre-op)

ICL	87.6%
LASIK	85.7%
SMILE	78.4%




Surgical Outcomes (ICL)

- UCVA



Refractive Stability

	ICL	LASIK	SMILE
Pre-op	-8.49D	-5.11D	-4.49D
Post-op 1M	-0.00D	0.07D	0.01D
Post-op 12M	-0.12D	-0.09D	-0.10D






- 731 Consecutive eyes which also suitable for LVC
- 5 centers
- Age 18-50 y/o (mean, 25.5 ± 6.0)
- Preop MRSE: $-5.23 \pm 1.27D$
 - Sphere $-4.56 \pm 1.25D$, Cylinder $1.27 \pm 1.17D$
- Preop CDVA: 1.0 or better
- Target refraction: Plano
- 447 non-toric
- 284 toric (cyl $>0.75D$)
- Refractions, VA, Vault, IOP, Scatter, ECD, HOA
- Followup $> 1 y$



Efficacy & Predictability



MRSE:

- Preop $-5.23 \pm 1.27D$ (-6.0 to 0.75)
- Postop: $+0.13 \pm 0.13D$ (-0.63 to 0.50)




Postop Cylinder Distribution

- Preop: $1.27 \pm 1.17D$ (0 to 4.50)
- Postop: $0.25 \pm 0.25D$ (0 to 0.75)




Efficacy & Safety



Postop UCVA





Preop BCVA / 术前BCVA




Efficacy & Safety



2Y Postop UCVA vs Preop BCVA



Visual Quality



Scatter

ICL



Preop OSI Postop OSI


1.0 0.7

LASIK



0.3 0.6


SMILE



0.7 1.9



Safety Parameters





- Stable IOP, vault, and endothelial cell density
- Wide variance in vaulting



Complications

- No vision threatening complications
- Improper sizing requiring ICL exchange 1.37%
 - ICL oversize: 6/731 (0.8%)
 - ICL undersize: 4/731 (0.5%)
- Cataract: 0%



Summary

- The refractive surgery market in China is far from saturation
- There're some interesting characteristics of Chinese market
- The surgical results are good and still improving in Aier hospitals
- ICL is very promising in low and moderate myopic eyes





Thank you...


第二届爱尔 EVO ICL 国际论坛

The 2nd Aier EVO ICL International Summit



Q&A Session 1





15-Minute Break




U.S. REFRACTIVE MARKET:
From LASIK to Lens-Based

STEPHEN SLADE, MD

Slade & Baker Vision
Houston, TX

EVO: Technology, Surgeon, Patient





Stephen G. Slade MD, FACS
September 14, 2023

Alcon, J&J, B&L, STAAR, Apple, Novartis, RxSight, CorneaGen, Vialase, Luminex

Glaukos, EyeBrain, Surgilum, Occumetrics, LensTec, Allotex, Omega Ophthalmics, Presbyopia Therapies

Early Adoption




- 1991 First LASIK in US
- 1996 FDA Lasik Approval
- 2005 FDA ICL Approval
- Courses, Papers, Texts



Picking Winners

- Is it unique, elegant?
- Do I believe in the product?
- Do I want this for my patients?
- Does it meet an unmet need, commercial potential?


Lesson Learned from LASIK: UCVA Drives Satisfaction



N = 12,936



• Schallhorn, AECOS 2016

Post UCVA Equal To Or Better Than Pre BSCVA




*Targeted For Emmetropia ($\pm 0.5D$)

Stability




Additive



Surgeon's Perspective

- Fast, straightforward procedure
- Not dose dependent
- Plays well with others
- Office OR?



A close-up photograph of a human eye, showing the iris and pupil. A bright, circular reflection is visible on the left side of the cornea. The text is overlaid on the right side of the eye.

Patient's Perspective!

- Wow Factor
- Average 20/30 at 1 hour
- Not visible, Removable
- Intact, No large incision
- Elective Surgery



Thank you!




VISION 2026

Establishing EVO ICL as The First Choice for Doctors and Patients

WARREN FOUST

Chief Operating Officer
STAAR Surgical Company



EVO ICL™

China

适用范围：适用于21-45岁成年人有晶状体眼的治疗，矫正/降低成年人-0.50D到-18.00D范围内的近视
中国代理人：达视眼科器材（上海）有限责任公司 生产企业：STAAR SURGICAL A.G瑞士斯达外科公司
禁忌内容请参见说明书
中心孔后房屈光型人工晶状体，国械注进20143185000
超过90%紫外线被拦截在360纳米波长以上
沪械广审（视）第281015-56434号

矫正近视



微创手术

拦截超过90%紫外线*

ICL 晶体植入术
近视矫正方式






APAC: STAAR is Achieving Broad-based Geographic Growth and Share Gains



Growth Variables


- > High myopia prevalence
- > Level of STAAR investment
- > EVO ICL adoption by largest hospital chains

EMEA: Progress Despite Macroeconomic Headwinds




- ### Growth Variables
- > Economic weakness
 - > Distributor vs. Direct
 - > Level of STAAR investment
 - > Other macroeconomic factors

Americas: Opportunity Abounds



ICL Sales by Country



Refractive Procedure Market Share, 2022



UNITED STATES

< 5%



22%

Americas Sales CAGR (2018-2022)

Growth Variables

- > Myopia prevalence
- > Level of STAAR investment
- > Economy

*Driving EVO ICL Awareness,
Our Marketing Works...*

 Will Levis has EVO ICL lenses.



 STAAR SURGICAL | EVO ICL

EVO ICL







Building Consumer Trust in EVO Safety and Efficacy

Joe & Kevin Jonas Chose EVO ICL




Partnership includes:

- ✓ 36 Stop Tour sponsorship, EVO ICL video ad played before every concert
- ✓ 8+ social posts on @JoeJonas, @KevinJonas, and @JonasBrothers social accounts (IG, TT, FB, TW)
- ✓ Reaching their 80M social media followers
- ✓ 12 month ad campaign rights via paid social, programmatic display, video, connected tv




Impact of Investments in EVO ICL Awareness and Digital Marketing

Delivering Unique Visitors to U.S. Doctor Finder (EVOICL.com)




Impact of Investments in EVO ICL Awareness and Digital Marketing - Past Six Quarters vs. Prior Year Period

Significant Increase in U.S. Doctor Finder Searches



EVO ICL Patient Journey is Too Often Incomplete (Current)



Process Improvements + Commercial Initiatives

Partnering with Best-In-Class Call Center to Complete EVO ICL Patient Discovery



Increasing Knowledge of STAAR's Customers to Optimize Segmentation

GOAL: Best serve meet/exceed each unique customer's needs and drive EVO ICL utilization

U.S. EVO ICL Customers

400+ Practices

600+ Surgeons



300K+

Annual U.S. Refractive Procedures



\$450M+

U.S. Refractive Procedure Revenue

Profits

\$1,821

EVO Incremental Profit Contribution

ALL SURGICAL SETTINGS

OBS is \$2,785

Patient Prices

89%

EVO Premium

EVO ICL \$8,680
vs. LVC \$4,688

Surgical Setting

20%

Practices have Office-Based Sterile Surgical Suite (OBS)

47%

Practices have Owned Ambulatory Surgery Center (ASC)

Other Qualitative and Quantitative Variables

Surgeon Competence and Confidence in Performing EVO ICL Procedure

- + Same Day Bilateral
- + Practice Spends Money on Refractive Marketing

Drive EVO ICL Adoption

PRE-OPERATIVE

Eye measurement and lens size selection

INTRA-OPERATIVE

Surgery

POST-OPERATIVE


Patient follow-up and understanding outcomes



STAAR recently established a structure and foundation for a World Class Training and Education Organization

Goal: Increase Surgeon Confidence and EVO ICL Utilization + One Document to Surgeon Customer on How STAAR will Provide Support and Education

Executing U.S. Pilots with Significant EVO ICL Growth Commitments



The number of pilots, pace of learnings and potential broader implementation are contemplated in STAAR's 18-24 month U.S. growth inflection timeline, i.e., 4Q24 or 1H25, as provided on June 6, 2023

Operational Excellence and Scale ...

We Are Delivering Our Lenses to Surgeons and Patients Faster in 2023

SERVICE LEVEL




TORIC MADE TO ORDER LENSES (MTO)

Number of Open MTO Lenses

Change from January 11, 2023 to August 31, 2023



Days Outstanding MTO Lenses



Existing and Planned through 2026

Manufacturing Capacity to Support \$800M+ Annual Sales




Capacity Expansion
Monrovia, CA

Existing and Planned Capacity


UNITS

Vision 2026: 1.6 Million



DOLLARS @ \$525/UNIT

Vision 2026: \$840 Million



Happy EVO ICL Patients and Surgeons!



Surgeon Panel: The Global EVO ICL Experience



**SCOTT D. BARNES,
MD**

Chief Medical Officer
STAAR Surgical
(Moderator)



**FRANK KERKOFF,
MD**

FYEO Medical



**STEPHEN SLADE,
MD**

Slade & Baker Vision



**ZHENG WANG,
MD**

Aier Eye Hospital
Group




**BLAKE WILLIAMSON,
MD**

Williamson Eye
Center



**ROGER ZALDIVAR,
MD**

Instituto Zaldivar



15-Minute Break



VISION 2026

Long Term Plan and Value Creation

PATRICK WILLIAMS

Chief Financial Officer

STAAR Surgical Company

01

STAAR's
Financial
Strength

02

Target Sales
and Operating
Model

03

Financial
Discipline

Fiscal 2023 Outlook

**3Q23
Sales**

Approximately

\$80M

**FY23
Sales**

Approximately

**\$320M
to
\$325M**

**FY23
Gross
Margin**

Approximately

78%

**FY23
CapEx**

Approximately

\$26M

We Know You Have Many Investment Choices


Small and Mid-Cap Public Company Universe

Market Caps \$300M to \$10 Billion



All Sectors


N = 2771



Healthcare Sector

N = 394

We Know You Have Many Investment Choices



We Know You Have Many Investment Choices

Small and Mid-Cap Public Company Universe

Market Caps \$300M to \$10 Billion

ALL

All Sectors
N = 2771


Healthcare Sector
N = 394

Positive
GAAP
Earnings

All Sectors
N = 1665



Healthcare Sector
N = 95



15%+ Sales
Growth
Consensus


All Sectors
N = 171



Healthcare Sector
N = 19



All Roads Lead to STAAR



Vision 2026 / Double-Digit Sales CAGR



TARGET SALES
MODEL

 STAARSURGICAL

Approximately

15%

TO

Approximately

20%

ANNUAL GROWTH RANGE Y/Y

3-Year Sales CAGR (2024-2026)




Approximately


\$500 TO \$550 MILLION

Fiscal 2026 Sales


Target Operating Model – Sales Sensitivities



- ✓ Pace of EVO ICL adoption down the diopter curve (EVO ICL owning -6D and above refractive vision correction)
- ✓ Country mix (Direct vs. Hybrid/Distributor)
- ✓ Success of U.S. Initiatives
- ✓ Success of initiatives introduced in other markets globally
- ✓ Macroeconomic environment (Particularly EMEA)



Vision 2026 / Double-Digit GAAP Operating Margin



ANNUAL OPERATING MARGIN
GAAP OPERATING MARGIN (2024-2026)



Fiscal 2026 Operating Income

Vision 2026 / Target Operating Model – Additional Details




~ 15% Sales
Growth CAGR
Scenario through
FY 2026E

+ ~\$180M ↻ Sales \$ Growth


+ ~700bps ↻ Operating Margin Expansion

	FY 2023 Outlook	FY 2026E	Change From FY23 Outlook	FY 2026E	Change From FY23 Outlook
Growth Scenario		~15% CAGR		~20% CAGR	
Sales	\$323M	\$500M	+\$177M	\$550M	+\$227M
Gross Margin	78%	81%	+300bps	81%	+300bps
OpEx	73%	69%	(400bps)	65%	(800bps)
Operating Income	5%	12%	+700bps	16%	+1100bps
G&A	23%	22%	(100bps)	20%	(300bps)
S&M	36%	35%	(100bps)	35%	(100bps)
R&D	14%	12%	(200bps)	10%	(400bps)
Tax Rate	25%-30%	25%-30%	-	25%-30%	-

STAAR Demonstrates Strong Sales Growth (in millions)




STAAR Knows How to Expand Operating Margin




STAAR Knows How to Generate Cash (in millions)

ADJUSTED EBITDA EX. SBC



BALANCE SHEET CASH



Vision 2026 / Our Target Sales and Operating Model

 STAARSURGICAL

Top 5%

Profitable &
15%+ Sales Growth

TARGET SALES AND
OPERATING MARGIN

 STAARSURGICAL

SALES

Approximately

15%

TO

Approximately

20%

ANNUAL GROWTH RANGE Y/Y

3-Year Sales CAGR (2024-2026)



Approximately

\$50 TO \$550 MILLION

Fiscal 2026
Sales

OPERATING MARGIN

Approximately

12%

TO

Approximately

16%

ANNUAL OPERATING MARGIN

GAAP OPERATING MARGIN (2024-2026)



Approximately

\$60 TO \$90 MILLION

Fiscal 2026
Operating Income



Closing Remarks


TOM FRINZI

Chair of the Board and CEO
STAAR Surgical Company

Vital Few Projects and Investments to Drive Growth




Evergreen and Refreshed as Data and Voice of Customer Dictates...




Select Growth Markets (3-Year CAGR, 2020-2022)

STAAR is a Global Growth Company



Emerging Markets and Rapidly Growing Middle Class and Wealthy STAAR Will Also Invest in the Next Stages of Growth



The Data


Among the 80 million new MACs [middle-class and affluent consumer], over 70% of this group will be from tier-3 cities and below, making lower-tier cities an increasingly important part of the market... Our research also shows that even during the relatively difficult last few years, Chinese consumers demonstrated a strong desire to trade up and an increased willingness to pay a premium for quality across product categories.

- BCG, *The Next Chapter in China's Consumer Story*, June 22, 2023

Consider these numbers. The middle class is the fastest-growing major segment of the Indian population in both percentage and absolute terms, rising at 6.3 percent per year between 1995 and 2021. It now represents 31 percent of the population and is expected to be 38 percent by 2031 and 60 percent in 2047


- *Economic Times, How the Middle Class will Play the Hero in India's Rise*, July 9, 2023

Project Roadrunner Will Ultimately Support \$1B+ Annual Sales



Vision 2026

IT'S OUR TIME...
IT'S EVO'S TIME!

 STAARSURGICAL

